JP2015534972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534972A5 JP2015534972A5 JP2015537289A JP2015537289A JP2015534972A5 JP 2015534972 A5 JP2015534972 A5 JP 2015534972A5 JP 2015537289 A JP2015537289 A JP 2015537289A JP 2015537289 A JP2015537289 A JP 2015537289A JP 2015534972 A5 JP2015534972 A5 JP 2015534972A5
- Authority
- JP
- Japan
- Prior art keywords
- lys
- arg
- phe
- gly
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 71
- 125000000539 amino acid group Chemical group 0.000 claims 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 26
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 25
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 21
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- -1 Ac-Lys-Gly- Lys Chemical compound 0.000 claims 9
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 claims 8
- 101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 claims 7
- 210000000056 organ Anatomy 0.000 claims 7
- 150000005693 branched-chain amino acids Chemical class 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- PQBHGSGQZSOLIR-RYUDHWBXSA-N Arg-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PQBHGSGQZSOLIR-RYUDHWBXSA-N 0.000 claims 3
- GSUFZRURORXYTM-STQMWFEESA-N Arg-Phe-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 GSUFZRURORXYTM-STQMWFEESA-N 0.000 claims 3
- 101100455752 Caenorhabditis elegans lys-3 gene Proteins 0.000 claims 3
- YSPZCHGIWAQVKQ-AVGNSLFASA-N Lys-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN YSPZCHGIWAQVKQ-AVGNSLFASA-N 0.000 claims 3
- 108010060534 MSH (11-13) Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000002216 heart Anatomy 0.000 claims 3
- 241000024188 Andala Species 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 108010054155 lysyllysine Proteins 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- XDEHMKQLKPZERH-BYPYZUCNSA-N (2s)-2-amino-3-methylbutanamide Chemical compound CC(C)[C@H](N)C(N)=O XDEHMKQLKPZERH-BYPYZUCNSA-N 0.000 claims 1
- RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 claims 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 201000000057 Coronary Stenosis Diseases 0.000 claims 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 claims 1
- OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 claims 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 claims 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 claims 1
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 claims 1
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 claims 1
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 claims 1
- IGRMTQMIDNDFAA-UWVGGRQHSA-N Lys-His Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IGRMTQMIDNDFAA-UWVGGRQHSA-N 0.000 claims 1
- FGMHXLULNHTPID-KKUMJFAQSA-N Lys-His-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 FGMHXLULNHTPID-KKUMJFAQSA-N 0.000 claims 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 1
- XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 claims 1
- ZJWIXBZTAAJERF-IHRRRGAJSA-N Lys-Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZJWIXBZTAAJERF-IHRRRGAJSA-N 0.000 claims 1
- YUAXTFMFMOIMAM-QWRGUYRKSA-N Lys-Lys-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O YUAXTFMFMOIMAM-QWRGUYRKSA-N 0.000 claims 1
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 claims 1
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 206010056675 Postoperative renal failure Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000012084 abdominal surgery Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000002255 anal canal Anatomy 0.000 claims 1
- 210000000709 aorta Anatomy 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 238000013132 cardiothoracic surgery Methods 0.000 claims 1
- 210000001168 carotid artery common Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000010102 embolization Effects 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 210000003372 endocrine gland Anatomy 0.000 claims 1
- 210000003499 exocrine gland Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 108010064235 lysylglycine Proteins 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 210000002356 skeleton Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716032P | 2012-10-19 | 2012-10-19 | |
| US61/716,032 | 2012-10-19 | ||
| PCT/EP2013/071935 WO2014060606A1 (en) | 2012-10-19 | 2013-10-21 | Alpha- and gamma-msh analogues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534972A JP2015534972A (ja) | 2015-12-07 |
| JP2015534972A5 true JP2015534972A5 (enExample) | 2016-12-08 |
| JP6429782B2 JP6429782B2 (ja) | 2018-11-28 |
Family
ID=49448156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537289A Active JP6429782B2 (ja) | 2012-10-19 | 2013-10-21 | アルファ−およびガンマ−ｍｓｈアナログ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9217023B2 (enExample) |
| EP (2) | EP2722340B1 (enExample) |
| JP (1) | JP6429782B2 (enExample) |
| CN (1) | CN104822702B (enExample) |
| AU (1) | AU2013333765B2 (enExample) |
| CA (1) | CA2888277C (enExample) |
| DK (1) | DK2722340T3 (enExample) |
| ES (1) | ES2538702T3 (enExample) |
| HU (1) | HUE025870T2 (enExample) |
| PL (1) | PL2722340T3 (enExample) |
| RU (1) | RU2668791C2 (enExample) |
| WO (1) | WO2014060606A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014060606A1 (en) | 2012-10-19 | 2014-04-24 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| WO2015162483A1 (en) * | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| HUE052977T2 (hu) * | 2014-04-22 | 2021-06-28 | Txp Pharma Gmbh | Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok) |
| WO2016066702A1 (en) * | 2014-10-28 | 2016-05-06 | Clinuvel Ag | Inflammatory disease |
| EP3212219A1 (en) * | 2014-10-28 | 2017-09-06 | Clinuvel AG | New indication for alpha-msh analogues |
| WO2017068020A1 (en) | 2015-10-20 | 2017-04-27 | Txp Pharma Gmbh | W-peptide analog |
| HUE059638T2 (hu) | 2019-05-10 | 2022-12-28 | Synact Pharma Aps | Ízületi gyulladásos betegségek kombinált kezelése |
| BR112023002608A2 (pt) | 2020-08-12 | 2023-05-09 | Txp Pharma Ag | Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade |
| JP2024522348A (ja) * | 2021-05-27 | 2024-06-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｍｃ３ｒアゴニストペプチド |
| IL309102A (en) | 2021-06-21 | 2024-02-01 | Synact Pharma Aps | Salts and formulations of phenyl pyrrole aminoguanidine |
| EP4565259A2 (en) * | 2022-08-03 | 2025-06-11 | Sightstream Biotherapeutics, Inc. | Novel melanocortin analogs |
| CN117106057B (zh) * | 2022-08-19 | 2024-11-01 | 南京汉欣医药科技有限公司 | 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5597894A (en) | 1995-06-05 | 1997-01-28 | The Louisiana State University Medical Center Foundation | Multi-tyrosinated somatostatin analogs |
| WO1998027113A2 (en) | 1996-12-17 | 1998-06-25 | Quadrant Holdings Cambridge Limited | Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5 |
| AU757658B2 (en) | 1998-03-09 | 2003-02-27 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| SE9801571D0 (sv) | 1998-05-05 | 1998-05-05 | Wapharm Ab | Melanokortin-1-receptorselektiva föreningar |
| WO2002006316A2 (en) | 2000-07-14 | 2002-01-24 | Zycos, Inc. | Alpha-msh related compounds and methods of use |
| US8912144B2 (en) | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
| ES2663916T3 (es) * | 2005-07-08 | 2018-04-17 | Ipsen Pharma | Ligandos de los receptores de la melanocortina |
| ES2407107T3 (es) * | 2005-08-26 | 2013-06-11 | Abbvie Inc. | Análogos de alfa-MSH terapéuticamente activos |
| WO2014060606A1 (en) | 2012-10-19 | 2014-04-24 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| HUE052977T2 (hu) | 2014-04-22 | 2021-06-28 | Txp Pharma Gmbh | Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok) |
| WO2015162486A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues |
| WO2015162483A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
-
2013
- 2013-10-21 WO PCT/EP2013/071935 patent/WO2014060606A1/en not_active Ceased
- 2013-10-21 CA CA2888277A patent/CA2888277C/en active Active
- 2013-10-21 PL PL13189492T patent/PL2722340T3/pl unknown
- 2013-10-21 EP EP13189492.5A patent/EP2722340B1/en active Active
- 2013-10-21 RU RU2015118576A patent/RU2668791C2/ru active
- 2013-10-21 EP EP15157262.5A patent/EP2944650A1/en not_active Withdrawn
- 2013-10-21 JP JP2015537289A patent/JP6429782B2/ja active Active
- 2013-10-21 CN CN201380062117.6A patent/CN104822702B/zh active Active
- 2013-10-21 AU AU2013333765A patent/AU2013333765B2/en active Active
- 2013-10-21 HU HUE13189492A patent/HUE025870T2/en unknown
- 2013-10-21 ES ES13189492.5T patent/ES2538702T3/es active Active
- 2013-10-21 US US14/058,790 patent/US9217023B2/en active Active
- 2013-10-21 DK DK13189492.5T patent/DK2722340T3/en active
-
2015
- 2015-11-24 US US14/951,305 patent/US9486495B2/en active Active
-
2016
- 2016-10-10 US US15/289,562 patent/US9951116B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5384342B2 (ja) | 癌のような変更された細胞遊走に関連する障害の治療のための薬理学的活性を有するペプチド | |
| JP2020502051A5 (enExample) | ||
| RU2015118576A (ru) | АНАЛОГИ АЛЬФА- и ГАММА-MSH | |
| ES2476842T3 (es) | Inhibidores polipept�dicos de HSP27 quinasa y usos de los mismos | |
| ES2962532T3 (es) | Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante | |
| JP2022009820A (ja) | α４β７インテグリンチオエーテルペプチドアンタゴニスト | |
| TWI653980B (zh) | 治療及預防缺血性傷害之組成物與方法 | |
| KR20170108936A (ko) | 신규한 α4β7 펩타이드 단량체 및 이량체 길항제 | |
| CN109195618A (zh) | 用于合成α4β7肽拮抗剂的方法 | |
| JP2017522362A5 (enExample) | ||
| JP2017535527A5 (enExample) | ||
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| JP2015523373A (ja) | ｅＩＦ４Ｅを標的化するための細胞浸透性ペプチド | |
| CN110691788B (zh) | 长效gip肽类似物 | |
| CA2052022A1 (en) | Peptides having thrombospondin-like activity and their therapeutic use | |
| JP2012111756A (ja) | エプチフィバチドの調製方法 | |
| Li et al. | Bicyclic stapled peptides based on p53 as dual inhibitors for the interactions of p53 with MDM2 and MDMX | |
| JPH02500517A (ja) | ペプチド化合物 | |
| Zhou et al. | Design and synthesis of nanofibers of self-assembled de novo glycoconjugates towards mucosal lining restoration and anti-inflammatory drug delivery | |
| CA2196053A1 (en) | Two non-contiguous regions contribute to nidogen binding to a single egf-like motif of the laminin .gamma.1 chain | |
| JP2012126720A5 (enExample) | ||
| Dong et al. | Synthesis and biological activities of fluorescent acridine‐containing HIV‐1 nucleocapsid proteins for investigation of nucleic acid‐NCp7 interactions | |
| Kutina et al. | Synthesis of new vasotocin analogues: effects on renal water and ion excretion in rats | |
| BR112020009113A2 (pt) | peptidomiméticos de grampo beta | |
| EP4568993A1 (en) | Peptides for the treatment of fibrosis |